Apixaban (eliquis) outperforms Rivaroxaban (xarelto) in venous thromboembolism bleeding risk
1. In the randomized COBRRA trial, apixaban was associated with substantially less clinically relevant bleeding than rivaroxaban in patients with ...
Tag: venous thromboembolism
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]
Pfizer’s Talzenna combo significantly delays progression in frontline prostate cancer Topline results from the Phase 3 TALAPRO-3 study indicate that ...
Reduced-dose apixaban noninferior to full dose for cancer-associated thrombosis
1. Among patients with active cancer and prior venous thromboembolism (VTE), extended treatment with reduced-dose apixaban demonstrated noninferior efficacy to ...
#VisualAbstract: Reduced-Dose was Not Non-Inferior to Full-Dose Direct Oral Anticoagulants in Venous Thromboembolism Patients
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Novel prophylactic anticoagulation scoring tool helps stratify patients following lower limb trauma
1. The 3-month symptomatic venous thromboembolism rate was 0.7% in patients with TRiP(cast) score < 7 and not receiving anticoagulation. ...
#VisualAbstract: Enoxaparin versus Placebo to Prevent Symptomatic Venous Thromboembolism in Hospitalized Older Adult Medical Patients
Click to read the study in NEJM ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
Indefinite anticoagulation for unprovoked venous thromboembolism is not cost-effective
1. In this Markov modeling study, indefinite anticoagulation for first unprovoked venous thromboembolism (VTE) cost $16,014 more per person than ...
Effect of thromboprophylaxis following COVID-19 hospitalization unclear
1. In this randomized controlled trial, the effects of thromboprophylaxis on clinical outcomes after coronavirus disease 2019 (COVID-19) hospitalization were ...
Low-dose low-molecular weight heparin comparable to intermediate-dose for risk of venous thromboembolism in peripartum women
1. Risk of venous thromboembolism in the antepartum and postpartum period was comparable between the intermediate- and low-dose low-molecular weight ...
#VisualAbstract: Aspirin associated with significantly higher rate of symptomatic venous thromboembolism compared to enoxaparin in patients undergoing hip or knee arthroplasty
1. In this random1. In this randomized controlled trial that included 9711 patients undergoing hip or knee arthroplasty, treatment ...
